Clinical trials: Immunodeficiency
Human Immunodeficiency Virus, Acquired Immunodeficiency Syndrome
Self-Test Strategies and Linkage Incentives to Improve ART and PrEP Uptake in Men
This is a randomized controlled trial to test a combination behavioral and biomedical interventions to improve the HIV prevention and care cascades in a population of mobile men in a high priority setting (fishermen in Kenya).
- Conditions
- Human Immunodeficiency Virus, Acquired Immunodeficiency Syndrome, HIV Infections, Sexually Transmitted Diseases, Viral
- Trial name
- NCT04772469
- Testing
- Provision of multiple self-tests, Small monetary incentives, Use of SMS/text reminders to motivate adherence to ART or PrEP
- Where
- Kenya
- Volunteers
- 934 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
HIV/AIDS
The Late Presenter Treatment Optimisation Study
The main purpose of this study is to compare two different types of HIV treatments, in terms of effectiveness and improvement of side effects, for patients who are diagnosed with a more advanced HIV infection.
- Trial name
- LAPTOP (NCT03696160)
- Testing
- Biktarvy, Symtuza
- Where
- 53 sites in Belgium, France and 5 more
- Volunteers
- 447 people
- Sponsor
- NEAT ID Foundation
Intravenous Drug Usage, HIV/AIDS
Building on Needle Exchange to Optimize Prevention & Treatment
There are several biomedical interventions that can help people who inject drugs (particularly those with or at risk for HIV), but these services often do not get to the people most in need.
- Trial name
- NCT03567174
- Testing
- Integrated care van (ICV)
- Where
- United States
- Volunteers
- 720 people
- Sponsor
- Johns Hopkins University
HIV Infections
Dolutegravir Pediatric Liquid Formulation Study
This is an open-label, single-center, single dose, non-randomized, sequential, fixed-sequence study, which will evaluate pharmacokinetics (PK) of dolutegravir (DTG) in healthy adult subjects.
- Trial name
- NCT03921723
- Testing
- Dolutegravir dispersible tablet, Dolutegravir oral suspension, Dolutegravir oral solution
- Where
- United Kingdom
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV Infections
Evaluating the Effect of CHanging EnfuvirtidE to Raltegravir in HIV Infected Subjects
The primary objective of this study is: To assess the virologic effect of changing enfuvirtide to MK-0518(raltegravir) in human immunodeficiency virus type 1(HIV-1) infected patients who have an undetectable level of serum human…
- Trial name
- CHEER (NCT00529243)
- Testing
- raltegravir
- Where
- 8 sites in United States
- Volunteers
- 52 people
- Sponsor
- Kaiser Permanente
Pre-Exposure Prophylaxis, HIV Infections
Testing Implementation Strategies to Improve Delivery of PrEP for Pregnant and Postpartum Women in Kenya
This study tests strategies for improving PrEP implementation in maternal and child health clinics using an interrupted time series.
- Conditions
- Pre-Exposure Prophylaxis, HIV Infections, Pregnancy Related
- Trial name
- PrEPARE (NCT05482360)
- Testing
- PrEP Optimization Interventions
- Where
- Kenya
- Volunteers
- 5,173 people, healthy volunteers welcome
- Sponsor
- University of Washington
Ataxia Telangiectasia
N-Acetyl-L-Leucine for Ataxia-Telangiectasia (A-T)
This is a multinational, multicenter, open-label, rater-blinded prospective Phase II study which will assess the safety and efficacy of N-Acetyl-L-Leucine (IB1001) for the treatment of Ataxia-Telangiectasia (A-T).
- Trial name
- NCT03759678
- Testing
- IB1001
- Where
- 4 sites in United States, Germany and 2 more
- Volunteers
- 17 people
- Sponsor
- IntraBio Inc
HIV Infections, Electronic Health Record
An Electronic Health Record-based Approach to Increase PrEP Knowledge and Uptake: the EMC2 PrEP Strategy
This study is being conducted to investigate a strategy that may improve knowledge and uptake of pre-exposure prophylaxis for HIV prevention (PrEP) among cisgender women in primary care.
- Conditions
- HIV Infections, Electronic Health Record, Primary Health Care
- Trial name
- NCT05709860
- Testing
- EMC2 PrEP Educational Tool, Discrete Scheduling of a Dedicated PrEP Visit
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Northwestern University
Hiv
HOPE in Action Prospective Multicenter, Clinical Trial of Deceased HIVD+ Kidney Transplants for HIV+ Recipients
The primary objective of this study is to determine if an HIV-infected deceased kidney donor (HIVD+) transplant is safe with regards to major transplant-related and HIV-related complications.
- Trial name
- NCT03500315
- Testing
- HIV D+/R+
- Where
- 29 sites in United States
- Volunteers
- 207 people
- Sponsor
- Johns Hopkins University
Anal Intraepithelial Neoplasia, High Grade Squamous Intraepithelial Neoplasia
VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions
This phase II trial studies the use of human papillomavirus (HPV) deoxyribonucleic acid (DNA) plasmids therapeutic vaccine VGX-3100 (VGX-3100) and electroporation in treating patients with human immunodeficiency virus…
- Conditions
- Anal Intraepithelial Neoplasia, High Grade Squamous Intraepithelial Neoplasia, HIV Positivity, Human Papillomavirus-16 Positive
- Trial name
- NCT03603808
- Testing
- Electroporation, HPV DNA Plasmids Therapeutic Vaccine VGX-3100, Laboratory Biomarker Analysis
- Where
- 8 sites in United States, Puerto Rico
- Volunteers
- 44 people
- Sponsor
- AIDS Malignancy Consortium
HIV/AIDS, Housing Problems
Enhanced Housing Placement Assistance
Randomized controlled trial of housing placement assistance for homeless persons with HIV
- Trial name
- EHPA (NCT03334825)
- Testing
- Enhanced housing placement assistance, Standard housing placement assistance
- Volunteers
- 236 people, healthy volunteers welcome
- Sponsor
- New York City Department of Health and Mental Hygiene
HIV Seropositivity, Metabolic Syndrome
Effect on Liver Fat and Metabolic Parameters When Switching a Protease Inhibitor or Efavirenz to Raltegravir
This study will provide data on the switch from a protease inhibitor or efavirenz to the new formulation of raltegravir (RAL) dosed once daily.
- Conditions
- HIV Seropositivity, Metabolic Syndrome, Fatty Liver
- Trial name
- OBERAL (NCT03374358)
- Testing
- Raltegravir
- Where
- Finland
- Volunteers
- 45 people
- Sponsor
- Helsinki University Central Hospital
HIV Infections
A Study Evaluating Implementation Strategies for the Delivery of Cabotegravir in Low and High-Volume PrEP Site in the United States
This is a two-arm study evaluating the impact of two implementation strategy conditions, dynamic implementation and routine implementation on the feasibility of delivering of Cabotegravir PrEP in low and high-volume PrEP sites in…
- Trial name
- PILLAR (NCT05374525)
- Testing
- APRETUDE, Cabotegravir OLI
- Where
- 17 sites in United States
- Volunteers
- 287 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV Infections
Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-2)
The aim of this study was to determine if virologically suppressed, human immunodeficiency virus type 1 (HIV-1) infected adults on an antiretroviral regimen (including 2 nucleoside reverse transcriptase inhibitors [NRTIs] plus a…
- Trial name
- NCT02422797
- Testing
- DTG 50 mg, RPV 25 mg, CAR
- Where
- 61 sites in United States, Argentina and 9 more
- Volunteers
- 518 people
- Sponsor
- ViiV Healthcare
Human Immunodeficiency Virus
Comparison of Virologic and Immunologic Responses to Raltegravir and Dolutegravir in the Gastrointestinal Tract of HIV-Positive Adults
This is a Phase IV, open label, observational study to compare the gastrointestinal tissue concentrations, inflammatory response, and viral replication of two integrase-inhibitors, raltegravir and dolutegravir, in HIV-infected…
- Trial name
- NCT02218320
- Testing
- Raltegravir, Dolutegravir, Colonoscopy with biopsy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of North Carolina, Chapel Hill
HIV/AIDS
Pre-exposure Prophylaxis (PrEP) at Home
This study is a randomized clinical trial of PrEP@Home, a home care system for Human Immunodeficiency Virus (HIV) Pre-Exposure Prophylaxis (PrEP).
- Trial name
- PrEP@Home (NCT03569813)
- Testing
- PrEP@Home System, Standard of Care
- Where
- 5 sites in United States
- Volunteers
- 318 people, healthy volunteers welcome
- Sponsor
- Emory University
HIV-1 Infection, HIV Infections
Maraviroc Plus Darunavir/Ritonavir for Treatment-Naïve Patients Infected With R5-tropic HIV-1
The objective of this study is to evaluate the safety and efficacy of a novel combination antiretroviral therapy regimen consisting of maraviroc plus darunavir/ritonavir in treatment-naive patients infected with R5-tropic HIV-1.
- Trial name
- MIDAS (NCT00993148)
- Testing
- maraviroc, darunavir, ritonavir
- Where
- 5 sites in United States
- Volunteers
- 25 people
- Sponsor
- Northwestern University
Hiv, HIV Infections
Effect of N-803 on B Cell Follicles in Antiretroviral Treated HIV Disease
N-803 has demonstrated ability to reactivate HIV from latency and can activate T cells and NK cells to clear those cells, thus reducing the reservoir.
- Conditions
- Hiv, HIV Infections, AIDS
- Trial name
- NCT04808908
- Testing
- N-803
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- University of Minnesota
HIV Infections
Scientific Evaluation of Peer Education and STD Treatment to Reduce the Spread of HIV in Zimbabwe
The purpose of this study is to determine whether community-based peer education and condom distribution combined with improved treatment of sexually transmitted infections are effective in reducing the spread of HIV infection in…
- Trial name
- NCT00390949
- Testing
- Peer education among commercial sex workers and clients, Condom distribution and promotion, Syndromic treatment of sexually transmitted infections
- Where
- Zimbabwe
- Volunteers
- 9,454 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Ulcerative Colitis
A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005)
The purpose of this study is to assess the safety and efficacy of tulisokibart in participants with moderately to severely active Ulcerative Colitis (UC).
- Trial name
- ARTEMIS-UC (NCT04996797)
- Testing
- Tulisokibart, Companion Diagnostic (CDx) Testing
- Where
- 88 sites in United States, Australia and 10 more
- Volunteers
- 178 people
- Sponsor
- Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.